Omeros (NASDAQ:OMER) Downgraded to Sell Rating by StockNews.com

Omeros (NASDAQ:OMER - Get Free Report) was downgraded by equities researchers at StockNews.com from a "hold" rating to a "sell" rating in a research note issued on Friday.

Other research analysts have also issued research reports about the company. D. Boral Capital restated a "buy" rating and issued a $36.00 target price on shares of Omeros in a report on Thursday, February 20th. Needham & Company LLC reissued a "hold" rating on shares of Omeros in a report on Friday, January 17th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Omeros presently has an average rating of "Moderate Buy" and an average target price of $22.50.

Omeros Stock Down 0.9 %

Shares of OMER stock traded down $0.08 during trading hours on Friday, hitting $9.02. 348,909 shares of the company's stock traded hands, compared to its average volume of 530,013. The stock has a market cap of $522.71 million, a PE ratio of -3.90 and a beta of 2.03. The stock's 50 day simple moving average is $8.70 and its 200 day simple moving average is $7.37. Omeros has a 12 month low of $2.61 and a 12 month high of $13.60.

Remove Ads

Institutional Trading of Omeros

A number of institutional investors have recently made changes to their positions in the stock. Truvestments Capital LLC boosted its stake in shares of Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company's stock valued at $31,000 after purchasing an additional 1,669 shares in the last quarter. Tower Research Capital LLC TRC boosted its position in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company's stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP purchased a new position in shares of Omeros during the 4th quarter worth approximately $46,000. BNP Paribas Financial Markets raised its position in shares of Omeros by 130.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company's stock worth $49,000 after acquiring an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management lifted its stake in shares of Omeros by 692.5% in the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company's stock valued at $50,000 after purchasing an additional 4,404 shares during the period. Hedge funds and other institutional investors own 48.79% of the company's stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.